Randomised phase II study with cetuximab in combination with 5-FU and cisplatin or carboplatin versus cetuximab in combination with paclitaxel and carboplatin for treatment of patients with relapsed or metastatic squamous cell carcinoma of the head and neck (CETMET trial).

Authors

Signe Friesland

Dep. of Oncology, Karolinska University Hospital, Stockholm, Sweden

Signe Friesland , Georgios Tsakonas , Claus Kristensen , Maria Herlestam Calero Moren , Hedda Haugen , Karin Soderstrom , Lena Specht

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2016 ASCO Annual Meeting

bookmark_border

Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02).

First Author: Makoto Tahara

insert_chart_outlined

Poster

2016 ASCO Annual Meeting

bookmark_border

Phase II trial of carboplatin/paclitaxel and cetuximab, followed by carboplatin/paclitaxel/cetuximab and erlotinib, in metastatic or recurrent squamous cell carcinoma of the head and neck.

First Author: Aarti K. Bhatia

insert_chart_outlined

Poster

2016 ASCO Annual Meeting

bookmark_border

TPF plus cetuximab (E) induction chemotherapy (ICT) followed by biochemoradiation (BCRT) with weekly E plus weekly cisplatin (P) or carboplatin (C) in stage III/IV squamous cell carcinoma of the head and neck (HNSCC): A randomized phase II EORTC trial.

First Author: Pol M. Specenier

insert_chart_outlined

Poster

2014 ASCO Annual Meeting

bookmark_border

Randomized phase II trial of weekly paclitaxel, carboplatin, cetuximab (PCC) versus cetuximab, docetaxel, cisplatin, and fluorouracil (C-TPF) in previously untreated patients with locally advanced head and neck squamous cell carcinoma.

First Author: Erminia Massarelli